The global mucormycosis treatment market is anticipated to grow at a considerable CAGR of 6.5% during the forecast period (2022-2028). The increasing disease prevalence for mucormycosis infections across the globe is one of the prime factors affecting and driving the market for mucormycosis treatment. For instance, as per the information provided by the Government of India around 40,845 cases of mucormycosis or black fungus were detected in 2020. Mucormycosis is considered a rapidly progressive and life-threatening invasive fungal disease. It mainly affects those with organ and bone marrow transplantation along with hematological malignancy and patients with diabetes, cancer, neutropenia, and skin trauma.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/mucormycosis-treatment-market
Moreover, to gain on the opportunity key players operating in the global mucormycosis treatment Market had been adopting strategies such as new launches to achieve major market share. For instance, in June 2021, Celon Laboratories which is considered one of the specialty biopharmaceutical manufacturers had introduced Amphotericin B Emulsion, for the treatment of Mucormycosis, which is commonly known as Black Fungus. Additionally, Amphotericin B is considered crucial to give an effective treatment of Mucormycosis, of which a sudden resurgence is being witnessed off late among covid19 patients, across India.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
o By Product
o By Diagnosis
o By Treatment
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- Cadila Pharmaceuticals, CELON LABS, Lifecare Innovations Pvt. Ltd., Merck Sharp & Dohme Corp., and Sun Pharmaceutical Industries Ltd.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Mucormycosis Treatment Market Report Segment
By Diagnosis
- Computed tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Tissue Biopsy
By Treatment
- Surgery
- Antifungal Drugs
By End-User
- Hospitals & Clinics
- Research Institutes
A full report of Mucormycosis Treatment Market is available at: https://www.omrglobal.com/industry-reports/mucormycosis-treatment-market
Mucormycosis Treatment Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Alembic Pharmaceuticals Ltd.
- Bharat Serums and Vaccines Ltd. (BSV)
- Cadila Pharmaceuticals
- CELON LABS
- Gilead Sciences, Inc.
- Lifecare Innovations Pvt. Ltd.
- Pfizer Ltd.
- Merck Sharp & Dohme Corp.
- Sun Pharmaceutical Industries Ltd.
- Taiwan Liposome Company, Ltd.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
